Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

TherapeuticsMD: Q2 Earnings Insights

  TherapeuticsMD (NASDAQ:TXMD) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

TherapeuticsMD (NASDAQ:TXMD) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

TherapeuticsMD missed estimated earnings by 13.16%, reporting an EPS of $-3.44 versus an estimate of $-3.04.

Revenue was up $5.56 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.72 which was followed by a 14.01% drop in the share price the next day.

Here’s a look at TherapeuticsMD’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -4 -4 -5 -5.5
EPS Actual -4.72 -4.5 -5.5 -5.5
Revenue Estimate 17.95M 29.39M 25.87M 22.11M
Revenue Actual 19.33M 18.68M 25.41M 23.00M

To track all earnings releases for TherapeuticsMD visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY

By Jelena Martinovic
April 2, 9:18 AM
Cannabinoids-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) reported on Tuesday year-end 2023 results and audited financial statements. The Canadian company reported CA$16.8 million ($12.3 million) in total revenue, up by 314% year-over-year. Avicanna mostly attributed a surge in revenue to the acquisition of Medical Cannabis by Shoppers from Shoppers Drug Mart and the launch of MyMedi.ca. "2023 was a tremendous year for Avicanna where we solidified our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca," he said. "We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars."

AVCNF